Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer.

Authors:
Hironobu Suto Keiichi Okano Minoru Oshima Yasuhisa Ando Hiroyuki Matsukawa Shigeo Takahashi Toru Shibata Hideki Kamada Hideki Kobara Akihito Tsuji Tsutomu Masaki Yasuyuki Suzuki

Pancreas 2022 03;51(3):269-277

From the Departments of Gastroenterological Surgery.

Objectives: Indications of preoperative treatment for resectable (R-) or borderline resectable (BR-) pancreatic ductal adenocarcinoma (PDAC) are unclear, and the protocol remains to be standardized.

Methods: Included 65 patients with R- and BR-PDAC with venous involvement (V-) received neoadjuvant chemoradiotherapy with S-1 and 50 Gy of radiation as the 5-week regimen. The outcomes of this group were compared with those of 52 patients who underwent S-1 and 30 Gy of radiation as the 2-week regimen, previously collected as our prospective phase II study.

Results: Compared with the 2-week regimen, there were no significant differences in the rate of protocol completion, adverse events, mortality and morbidity, or R0 resection in the 5-week regimen. In subgroup analyses of R-PDAC, there were no significant differences in overall survival and recurrence-free survival between the groups. In contrast, the 5-week regimen had significantly better overall survival and recurrence-free survival than the 2-week regimen for BRV-PDAC. Similar results were observed after propensity score matching analysis.

Conclusions: The 5-week regimen of neoadjuvant chemoradiotherapy has good clinical efficacy and safety for R- and BRV-PDAC. The 5-week regimen could achieve better outcomes than the 2-week regimen for BRV-PDAC. In contrast, both regimens achieved similar outcomes for R-PDAC.

Download full-text PDF

 Source
http://dx.doi.org/10.1097/MPA.0000000000002011DOI Listing
March 2022

Publication Analysis

Top Keywords

5-week regimen
20
2-week regimen
16
regimen
9
resectable borderline
8
neoadjuvant chemoradiotherapy
8
efficacy safety
8
survival recurrence-free
8
recurrence-free survival
8
regimen brv-pdac
8
borderline resectable
8
s-1 radiation
8
5-week
5
safety brv-pdac
4
collected prospective
4
adverse events
4
completion adverse
4
protocol completion
4
rate protocol
4
differences rate
4
regimen differences
4

Keyword Occurance

Similar Publications

Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer.

Authors:
Hironobu Suto Keiichi Okano Minoru Oshima Yasuhisa Ando Hiroyuki Matsukawa Shigeo Takahashi Toru Shibata Hideki Kamada Hideki Kobara Akihito Tsuji Tsutomu Masaki Yasuyuki Suzuki

Pancreas 2022 03;51(3):269-277

From the Departments of Gastroenterological Surgery.

Objectives: Indications of preoperative treatment for resectable (R-) or borderline resectable (BR-) pancreatic ductal adenocarcinoma (PDAC) are unclear, and the protocol remains to be standardized.

Methods: Included 65 patients with R- and BR-PDAC with venous involvement (V-) received neoadjuvant chemoradiotherapy with S-1 and 50 Gy of radiation as the 5-week regimen. The outcomes of this group were compared with those of 52 patients who underwent S-1 and 30 Gy of radiation as the 2-week regimen, previously collected as our prospective phase II study. Read More

View Article and Full-Text PDF
March 2022
Similar Publications

Assessment of inhalation toxicity of cigarette smoke and aerosols from flavor mixtures: 5-week study in A/J mice.

Authors:
Ee Tsin Wong Karsta Luettich Lydia Cammack Chin Suan Chua David Sciuscio Celine Merg Maica Corciulo Romain Piault Kumar Ashutosh Cameron Smith Patrice Leroy Fabian Moine Anneke Glabasnia Pierrick Diana Cecilia Chia Ching Keong Tung Nikolai Ivanov Julia Hoeng Manuel Peitsch Kyeonghee Monica Lee Patrick Vanscheeuwijck

J Appl Toxicol 2022 May 11. Epub 2022 May 11.

PMI R&D, Philip Morris Products S.A, Neuchâtel, Switzerland.

Most flavors used in e-liquids are generally recognized as safe for oral consumption, but their potential effects when inhaled are not well characterized. In vivo inhalation studies of flavor ingredients in e-liquids are scarce. A structure-based grouping approach was used to select 38 flavor group representatives (FGR) on the basis of known and in silico-predicted toxicological data. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Treatment with bortezomib for recurrent proliferative glomerulonephritis with monoclonal IgG deposits in kidney allograft. Case report and review of the literature.

Authors:
Rikako Oki Kohei Unagami Sekiko Taneda Toshio Takagi Hideki Ishida

J Nephrol 2022 05 6;35(4):1289-1293. Epub 2022 May 6.

Department of Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Proliferative glomerulonephritis with monoclonal immunoglobulin IgG deposits (PGNMID) is an already described form of renal involvement by monoclonal gammopathy. PGNMID is known to recur in kidney allografts. Bortezomib has shown clinical success in the treatment of multiple myeloma. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.

Authors:
Sabina Kersting Julie Dubois Kazem Nasserinejad Johan A Dobber Clemens Mellink Anne-Marie F van der Kevie-Kersemaekers Ludo M Evers Fransien de Boer Harry R Koene John Schreurs Marjolein van der Klift Gerjo A Velders Ellen van der Spek Hanneke M van der Straaten Mels Hoogendoorn Michel van Gelder Eduardus F M Posthuma Hein P J Visser Ilse Houtenbos Cecile A M Idink Djamila E Issa Ellen C Dompeling Henk C T van Zaanen Hendrik Veelken Henriette Levenga Lidwine W Tick Wim E Terpstra Sanne H Tonino Michelle Boyer Mehrdad Mobasher

Lancet Haematol 2022 Mar;9(3):e190-e199

Genentech, South San Francisco, CA, USA.

Background: Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles of venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated patients with chronic lymphocytic leukaemia who were unfit for fludarabine-based treatment, and whether this could be guided by minimal residual disease status.

Methods: We conducted an open-label, randomised, parallel-group, phase 2 trial (HOVON 139/GiVe) at 25 hospitals in the Netherlands. Read More

View Article and Full-Text PDF
March 2022
Similar Publications

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.

Authors:
Constantine S Tam John N Allan Tanya Siddiqi Thomas J Kipps Ryan Jacobs Stephen Opat Paul M Barr Alessandra Tedeschi Livio Trentin Rajat Bannerji Sharon Jackson Bryone J Kuss Carol Moreno Edith Szafer-Glusman Kristin Russell Cathy Zhou Joi Ninomoto James P Dean William G Wierda Paolo Ghia

Blood 2022 06;139(22):3278-3289

Università Vita-Salute San Raffaele, Milan, Italy; and.

CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. Patients received 3 cycles of ibrutinib lead-in then 12 cycles of ibrutinib plus venetoclax (oral ibrutinib [420 mg/d]; oral venetoclax [5-week ramp-up to 400 mg/d]). Read More

View Article and Full-Text PDF
June 2022
Similar Publications
}